DAX19.790 -4,1%ESt504.656 -4,6%Top 10 Crypto10,99 -1,9%Dow37.966 -0,9%Nas15.603 +0,1%Bitcoin73.125 +0,8%Euro1,0976 +0,5%Öl65,03 +1,0%Gold3.000 +0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Tesla A1CX3T Allianz 840400 Amazon 906866 Apple 865985 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 Lufthansa 823212 Infineon 623100 Deutsche Bank 514000 Volkswagen (VW) vz. 766403 Microsoft 870747 Berkshire Hathaway A0YJQ2
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Zollstreit: DAX beendet Handel nach Kursmassaker über Tagestief -- Wall Street volatil -- EU bietet USA Freihandelsdeal -- Bitcoin fällt unter 80.000-Dollar-Marke -- QIAGEN, Goldpreis im Fokus
Top News
Zollchaos sorgt für Marktturbulenzen: In diesen Währungen finden Anleger sichere Häfen Zollchaos sorgt für Marktturbulenzen: In diesen Währungen finden Anleger sichere Häfen
Zölle und OPEC+ sorgen für Gegenwind: Goldman Sachs kappt Ölpreisprognosen Zölle und OPEC+ sorgen für Gegenwind: Goldman Sachs kappt Ölpreisprognosen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Syndax Pharmaceuticals Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
10,00 EUR -1,70 EUR -14,53 %
STU
11,01 USD -0,23 USD -2,05 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.886,20 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2AFL6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS87164F1057

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSNDX

Syndax Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development
PR NewswireSyndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
PR NewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR NewswireSyndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023
PR NewswireSyndax Announces Participation at Upcoming Investor Conferences
PR NewswireSyndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference
PR NewswireSyndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting
PR NewswireSyndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia
PR NewswireSyndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
PR NewswireSyndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer
PR NewswireSyndax Announces Participation at Evercore ISI Annual HealthCONx Conference
PR NewswireSyndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias
PR NewswireSyndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
PR NewswireSyndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022
PR NewswireSyndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer
PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences
PR NewswireSyndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day
PR NewswireSyndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022
Wer­bung

Syndax Pharmaceuticals News

Syndax Pharmaceuticals News: auf dieser Seite finden Sie alle Syndax Pharmaceuticals News und Nachrichten zur Syndax Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Syndax Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Syndax Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.